Chronic News and Research

RSS

George Washington University SPHHS launches Childhood Asthma Leadership Coalition

Today the George Washington University School of Public Health and Health Services (SPHHS) announced the launch of the Childhood Asthma Leadership Coalition, a multi-sector group of advocates and experts dedicated to raising awareness and advancing public policies to improve the health of children who suffer from asthma.

30 Aug 2012

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Israel's Ministry of Health (MOH) has approved two Phase I/II clinical trials to assess the safety and efficacy of INFRADURE in patients with hepatitis C.

30 Aug 2012

FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy

Aerial BioPharma, a biopharmaceutical company focused on developing biologics and small molecules for conditions in the central nervous system, has received orphan drug designation for its narcolepsy drug in development.

30 Aug 2012

Jobless working-age people with diabetes less likely to adhere to their medications

If you're diabetic or prone to diabetes, having a steady job appears to be good for your health, and not just because of the insurance coverage.

30 Aug 2012

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Sleep disorders are a large area. We are focused on one particular type of sleep disturbance called “non-restorative” sleep. People with this problem do sleep, but they don’t wake up feeling refreshed or feeling that their sleep has had the restorative effects of healthy sleep.

29 Aug 2012

Johns Hopkins' Armstrong Institute for Patient Safety and Quality receives Moore Foundation grant

Johns Hopkins' Armstrong Institute for Patient Safety and Quality has received an $8.9 million grant from the Gordon and Betty Moore Foundation, the first award given as part of an ambitious new $500 million, 10-year program designed to eliminate all preventable harms that patients experience in the hospital.

29 Aug 2012

Trudeau Institute study holds promise for improved prevention and treatment of bacterial infections

New research from the laboratory of Dr. Andrea Cooper at the Trudeau Institute, just published in the European Journal of Immunology, holds promise for the improved prevention and treatment of bacterial infections and the life-threatening complications of chronic inflammation that can result from them.

29 Aug 2012

VA report shows improvement in gender disparities in 12 out of 14 HEDIS measures

The Department of Veterans Affairs (VA) has released a report that shows improvement in gender disparities in 12 out of 14 Healthcare Effectiveness Data and Information Set (HEDIS) measures in VA since 2008.

29 Aug 2012

GeneTex to introduce new antibody against hypoxia-inducible factor 1alpha

GeneTex, Inc., a leading manufacturer of antibodies, has announced that they will be launching a new antibody against HIF1a (hypoxia-inducible factor 1alpha).

29 Aug 2012

Altheus Therapeutics initiates enrollment in Zoenasa Phase 2 study for ulcerative colitis

Altheus Therapeutics announced today it has randomized its first patient in a comparator-controlled Phase 2 efficacy study of Zoenasa, a novel combination therapy for ulcerative colitis (UC).

29 Aug 2012

Eplerenone shown to reduce cumulative heart failure hospitalisations

Pfizer Inc. (NYSE: PFE) announced results from a new post-hoc analysis of the EMPHASIS-HF trial showing statistically significant reductions in rates of cumulative heart failure (HF) hospitalisations in patients with HF treated with eplerenone compared with placebo on a background of standard optimal therapy.1 The results were presented at The European Society of Cardiology Congress (ESC) in Munich.

28 Aug 2012

Three Pulmatrix PUR118 clinical studies on COPD, asthma to be presented at ERS Annual Congress

Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALM therapeutic, the first treatment developed utilizing its iSPERSE inhaled drug platform, will be presented at the European Respiratory Society (ERS) Annual Congress taking place September 1-5, 2012, in Vienna, Austria.

28 Aug 2012

High doses of vitamin B3 stimulate CEBPE gene, enhance WBCs’ ability to combat staph infections

Cedars-Sinai researchers have found that a common vitamin may have the potential to provide a powerful weapon to fight certain "superbugs," antibiotic-resistant staph infections that health experts see as a threat to public health.

28 Aug 2012

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

28 Aug 2012

Copeptin estimates prognosis in patients with heart failure

Copeptin predicts prognosis in patients with heart failure, according to research presented at the ESC Congress today, August 25, by Professor Stefan St-rk from Germany.

28 Aug 2012

Study shows why some fats may encourage growth of harmful bacteria in the digestive system

All dietary fats are not created equal. Some types of fats have been linked to ailments like heart disease and diabetes, while others, like those often found in plants and fish, have well documented health benefits.

28 Aug 2012

Disruption of circadian rhythm can inhibit blood vessel growth in the body

Disruptions to the circadian rhythm can affect the growth of blood vessels in the body, thus causing illnesses such as diabetes, obesity, and cancer, according to a new study from Linköping University and Karolinska Institutet in Sweden.

28 Aug 2012

Spinal cord stimulation could become novel treatment option for heart failure

Spinal cord stimulation improves heart function and could become a novel treatment option for heart failure, according to research presented at the ESC Congress 2012 today, August 25, by Professor Hung-Fat Tse from Hong Kong.

28 Aug 2012

Being physically fit also increases the chances of aging healthily

Being physically fit during your 30s, 40s, and 50s not only helps extend lifespan, but it also increases the chances of aging healthily, free from chronic illness, investigators at UT Southwestern Medical Center and The Cooper Institute have found.

28 Aug 2012

Novartis receives EC approval for Jakavi to treat myelofibrosis

Incyte Corporation today announced that its strategic collaborator, Novartis, received approval from the European Commission for Jakavi (INC424, ruxolitinib), an oral JAK 1 and JAK 2 inhibitor discovered by Incyte, for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

28 Aug 2012

Chronic News and Research

George Washington University SPHHS launches Childhood Asthma Leadership Coalition

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy

Jobless working-age people with diabetes less likely to adhere to their medications

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Johns Hopkins' Armstrong Institute for Patient Safety and Quality receives Moore Foundation grant

Trudeau Institute study holds promise for improved prevention and treatment of bacterial infections

VA report shows improvement in gender disparities in 12 out of 14 HEDIS measures

GeneTex to introduce new antibody against hypoxia-inducible factor 1alpha

Altheus Therapeutics initiates enrollment in Zoenasa Phase 2 study for ulcerative colitis

Eplerenone shown to reduce cumulative heart failure hospitalisations

Three Pulmatrix PUR118 clinical studies on COPD, asthma to be presented at ERS Annual Congress

High doses of vitamin B3 stimulate CEBPE gene, enhance WBCs’ ability to combat staph infections

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Copeptin estimates prognosis in patients with heart failure

Study shows why some fats may encourage growth of harmful bacteria in the digestive system

Disruption of circadian rhythm can inhibit blood vessel growth in the body

Spinal cord stimulation could become novel treatment option for heart failure

Being physically fit also increases the chances of aging healthily

Novartis receives EC approval for Jakavi to treat myelofibrosis

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News